A new advanced gene therapy for patients with beta-thalassemia is underway at Brotzu: the goal is to eliminate transfusions.

The therapy, recently recognized at the European and national levels, uses the patient's own stem cells that have been appropriately modified to allow the body to produce functional hemoglobin, thus reducing or potentially eliminating the need for continuous transfusions.

This is a highly specialized procedure that requires centers with multidisciplinary expertise, intensive care units, accredited systems for cell collection and processing, and personnel with specific training in hematopoietic transplantation.

Further details will be provided on Tuesday morning during a press conference attended by the President of the Region, Alessandra Todde, along with company executives and clinical managers involved in the gene therapy process.

(Unioneonline)

© Riproduzione riservata